On June 27, 2023, NexPoint Advisors, L.P. announced that it has sent an open letter to Paratek Pharmaceuticals Inc, stating that it plans to withhold its votes against all 3 board members nominated by the Company. In addition, NexPoint Advisors stated that it expressed its concerns with the Company’s long-term underperformance, the board’s failure to hold management accountable for such underperformance and the process the board may have undertaken in approving a sale of the Company to Gurnet Point Capital LLC in a deal that upon preliminary review appears to grossly overcompensate Company leadership to the detriment of stockholders and the Company stated that it intend to carefully scrutinize the proposed acquisition once more information regarding the sale process and valuation is made available in the proxy statement which should be filed soon by the Company with the Securities Exchange Commission and if it believe that the Proposed Acquisition is unfair to public stockholders, it will vote against the proposed acquisition at the annual meeting of shareholders scheduled to be held on July 6, 2023.